Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.76 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883670 | 1.00 | EGFR (0.76) | EGFRERBB2METKDRLCK | |
| SCHEMBL12896111 | 0.91 | EGFR (0.70) | EGFRERBB2METKDRLCK | |
| SCHEMBL14393666 | 0.90 | EGFR (0.68) | EGFRERBB2METKDRLCK | |
| SCHEMBL4552653 | 0.86 | EGFR (1.00) | EGFRERBB2MET | |
| SCHEMBL4552654 | 0.86 | EGFR (1.00) | EGFRERBB2MET | |
| SCHEMBL12883679 | 0.79 | ERBB2 (0.53) | EGFRERBB2METKDRLCK | |
| SCHEMBL1219643 | 0.79 | ERBB2 (0.53) | EGFRERBB2METKDRLCK | |
| SCHEMBL2447488 | 0.79 | EGFR (1.00) | EGFRERBB2MET | |
| SCHEMBL1220182 | 0.73 | EGFR (0.65) | EGFRERBB2KDRLCK | |
| SCHEMBL1219612 | 0.73 | EGFR (0.65) | EGFRERBB2KDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2058314-A1 | Pyrrolotriazine compounds as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2009-05-13 | — | — | EP | claimed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| CN-1922182-B | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-08-18 | — | — | CN | disclosed |
| EP-1699797-B1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2058314-A1 | Pyrrolotriazine compounds as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1922182-A | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-02-28 | — | — | CN | disclosed |
| US-7141571-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | EGFR 4/4885ERBB2 1/4885MET 213/4885 |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | EGFR 4/4885ERBB2 1/4885MET 213/4885 |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | ERBB2, ERBB4, ERBB3 | EGFR 4/4885ERBB2 1/4885MET 213/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | EGFR 4/4885ERBB2 1/4885MET 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.